Resources with keywords: covid-19
CDC endorsing that people 65 years and older and those who are moderately or severely immunocompromised receive a second dose of 2024-2025 COVID-19 vaccine six months after their first dose.
Gulick RM, Pau AK, Daar E, Evans L, Gandhi RT, Tebas P, Ridzon R, Masur H, Lane HC; NIH COVID-19 Treatment Guidelines Panel; Adimora AA, Baker J, Kreuziger LB, Bedimo R, Belperio P, Bhalla A, Burgess T, Campbell D, Cantrill S, Chew K, Chiotos K, Coopersmith C, Davey R, Dzierba A, Eisnor D, Eschenauer G, Francis J, Gallagher J, Glidden D, Goldenberg N, Grund B, Han A, Hardy E, Harrison C, Henderson L, Higgs E, Hinkson C, Hughes B, Johnson S, Keller M, Kim A, Knight R, Kuriakose S, Lennox J, Lerner A, Levy M, Li J, MacBrayne C, Martin G, Nadig N, Nason M, Patel P, Pavia A, Proschan M, Schulert G, Seam N, Sheikh V, Simpson S, Singh K, Swindells S, Tien P, Uyeki T, Waghmare A, Wolfe C, Yazdany J, Aberg J.
In March 2020, the White House Coronavirus Task Force determined that clinicians in the United States needed expert treatment guidelines to optimally manage patients with COVID-19, a potentially life-threatening disease caused by a new pathogen for which no specific treatments were known to be effective.
Key Points include strategies for contingency capacity
This guidance applies to all U.S. settings where healthcare is delivered, including nursing homes and home health. The recommendations in this guidance continue to apply after the expiration of the federal COVID-19 Public Health Emergency.
Currently there remains a lack of regulatory alignment among OSHA, the Food and Drug Administration (FDA), and the National Institute for Occupational Safety and Health (NIOSH) regarding respirator approval for use in health care.
This guidance is intended for clinical laboratory and support staff who handle or process specimens associated with COVID-19.
Discusses the disease, prevention via vaccination, signs and symptoms, complications, testing and diagnosis, who is most at risk, etc.
Gillum D, et al.
The US government issued a long-awaited policy update last month intended to better manage the hazards associated with risky biological research.
International experts reach consensus on a set of descriptors to describe how pathogens are transmitted through the air and the related modes of transmission.
